Butyric Acid

Butyric Acid

SCHEMBL2901210

CCC(CO)C(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.56
HDAC2 Q92769 2/20 0.56
FFAR3 O14843 1/20 0.56
HDAC3 O15379 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
CA2 P00918 1/20 0.48
MAPK1 P28482 1/20 0.48
TDP1 Q9NUW8 3/20 0.44
CHRM1 P11229 1/20 0.44
AKR1A1 P14550 1/20 0.44
CHRM3 P20309 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
ADRA1A P35348 1/20 0.44
HRH1 P35367 1/20 0.44
DRD3 P35462 1/20 0.44
SLC6A3 Q01959 1/20 0.44
SLC1A1 P43005 2/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL11032758 1.00 HDAC1 (0.56) HDAC1HDAC2FFAR3HDAC3HDAC8
Butyric Acid SCHEMBL8860767 1.00 HDAC1 (0.56) HDAC1HDAC2FFAR3HDAC3HDAC8
Butyric Acid SCHEMBL8860524 1.00 HDAC1 (0.56) HDAC1HDAC2FFAR3HDAC3HDAC8
Butyric Acid SCHEMBL2898882 1.00 HDAC1 (0.56) HDAC1HDAC2FFAR3HDAC3HDAC8
Butyric Acid SCHEMBL4631692 0.89 HDAC1 (0.65) HDAC1HDAC2FFAR3HDAC3HDAC8
SCHEMBL247706 0.86
SCHEMBL10634919 0.86
SCHEMBL40620 0.86
Butyric Acid SCHEMBL4630360 0.84 HDAC1 (0.59) HDAC1HDAC2FFAR3HDAC3HDAC8
SCHEMBL5159552 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10248019-B2 Pattern forming method, actinic ray-sensitive or radiation-sensitive resin composition and resist film FUJIFILM CORPORATION (JP) 2019-04-02 US disclosed
US-20130122427-A1 PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM FUJIFILM CORPORATION (JP) 2013-05-16 US disclosed
US-8440666-B2 Pyridazinone compounds and P2X7 receptor inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-05-14 US disclosed
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS NISSAN CHEMICAL INDUSTRIES LIMITED 2010-11-11 US disclosed
US-20080269285-A1 Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2008-10-30 US disclosed
US-5631259-A PURINE BASE DERIVATIVES FOR NUCLEOSIDES HOECHST AKTIENGESELLSCHAFT (DE) 1997-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS P2RY1, P2RX7, P2RX1 HDAC1 2983/4885HDAC2 2816/4885FFAR3 395/4885
US-20080269285-A1 Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same GBA1, GAA, MAN2B1 HDAC1 123/4885HDAC2 190/4885FFAR3 1169/4885
US-10248019-B2 Pattern forming method, actinic ray-sensitive or radiation-sensitive resin composition and resist film ACTR3, RXRA, RARA HDAC1 4004/4885HDAC2 4468/4885FFAR3 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.